2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕。
日前，含LBA在内的大会日程安排均已公布，「肿瘤资讯」整理了消化道领域入选本次ESMO大会LBA（Latest Breaking Abstract）的重磅研究，邀诸位一同细品！
专场：Proffered Paper session
Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
局部晚期 dMMR结肠癌的新辅助免疫检查点抑制：NICHE-2 研究
发言人：Myriam Chalabi (Amsterdam, Netherlands)
Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
LEAP-002 3期研究的主要结果：仑伐替尼加帕博利珠单抗vs.仑伐替尼作为晚期肝细胞癌 (aHCC) 的一线 (1L) 治疗
发言人：Richard S. Finn (Los Angeles, United States of America)
Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲ trial
卡瑞利珠单抗 (C) 加 rivoceranib (R) （即apatinib，阿帕替尼）vs.索拉非尼 (S) 作为不可切除肝细胞癌 (uHCC) 的一线治疗：一项随机 Ⅲ 期试验
发言人：秦叔逵，南京金陵医院，中国
Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
RATIONALE-301 的最终分析：替雷利珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的随机 3 期研究
发言人：Masatoshi Kudo (Osaka, Japan)
FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: phase III CAIRO5 study of the Dutch Colorectal Cancer Group
FOLFOX/FOLFIRI联合贝伐珠单抗或帕尼单抗治疗最初不可切除的结直肠肝转移 (CRLM) 、左侧、RAS/BRAFV600E野生型肿瘤患者：荷兰结直肠癌组的III期 CAIRO5研究
发言人：Marinde J. Bond (Utrecht, Netherlands)
Phase III study with FOLFIRI/Cetuximab versus FOLFIRI/Cetuximab followed by Cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: the ERMES Study (NCT02484833).
FOLFIRI/西妥昔单抗序贯西妥昔单抗(Cet) vs. FOLFIRI/西妥昔单抗一线治疗RAS 和 BRAF 野生型（wt）转移性结直肠癌（mCRC）患者：ERMES III 期研究（NCT02484833）
发言人：Carmine Pinto (Reggio Emilia, Italy)
Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial.
Avelumab vs. 标准二线化疗治疗微卫星不稳定性 (MSI) 转移性结直肠癌 (mCRC) 患者：SAMCO-PRODIGE 54 随机 II 期试验
发言人：Julien Taieb (Paris, France)
Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
RLY-4008（一种高选择性 FGFR2 抑制剂）在 FGFR2 融合或重排 (f/r)、FGFR 抑制剂 (FGFRi) 初治胆管癌 (CCA) 患者 (pts) 中的疗效：ReFocus 试验
发言人：Antoine Hollebecque (Villejuif, Cedex, France)
Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic Pancreatic Ductal Adenocarcinoma: Results of the randomized phase III PRODIGE 65–UCGI 36–GEMPAX UNICANCER study
FOLFIRINOX治疗失败或不耐受后的转移性胰腺导管腺癌患者吉西他滨+紫杉醇vs.单独吉西他滨治疗的评估：随机 III 期 PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER 研究的结果
发言人：Christelle De la Fouchardiere (Lyon, France)
Proffered Paper session 2: GI, lower digestive
KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
KRYSTAL-1：adagrasib(MRTX849) 联合或不联合西妥昔单抗在携带 KRASG12C 突变的晚期结直肠癌 (CRC) 患者中的最新疗效和安全性
发言人：Samuel J. Klempner (Boston, United States of America)
FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
FRESCO-2——一项全球 3 期多区域临床试验 (MRCT)：评估呋喹替尼对难治性转移性结直肠癌患者的疗效和安全性
Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQTOR study (GETNE 1206)
在晚期进展性panNETs 中比较依维莫司序贯化疗 (CT) +链脲佐菌素 (STZ)-5FU的疗效和安全性 ：随机开放标签 III 期SEQTOR 研究 (GETNE 1206)
发言人：Ramon Salazar (Hospitalet de Llobregat, Spain)
Mini Oral session
HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: a multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
HR070803 + 5-FU/LV vs. 安慰剂 + 5-FU/LV 在吉西他滨难治性局部晚期或转移性胰腺癌的二线治疗效果：一项多中心、随机、双盲、平行对照的 III 期试验（HR -IRI-APC)
发言人：王理伟教授，上海交通大学医学院附属仁济医院，中国
BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
BREAKWATER safety lead-in (SLI)：encorafenib (E) + 西妥昔单抗 (C) +化疗 (chemo)用于 BRAFV600E 转移性结直肠癌 (mCRC)
发言人：Josep Tabernero (Barcelona, Spain)
Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
MOUNTAINEER 2 期研究的其他分析：tucatinib和曲妥珠单抗治疗HER2 阳性 mCRC
发言人：John H. Strickler (Durham, United States of America)
Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial
影像学和 CEA随访在已切除的结直肠癌 (CRC) 患者中的预后效果——最终结果和无复发生存期 (RFS)： PRODIGE 13 FFCD III 期试验
发言人：Come Lepage (Dijon, France)
Mini Oral session: NETs and endocrine tumours
Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): the PRODIGE 41-BEVANEC randomized phase II study
晚期神经内分泌肿瘤(NEC)患者(pts)铂类（依托泊苷）治疗失败后贝伐珠单抗 (B)+FOLFIRI治疗结果：PRODIGE 41-BEVANEC 随机 II 期研究
发言人：Thomas A. Walter (Lyon, France)
ESMO大会开幕在即，以上LBA哪一项最值得期待？快在评论区留言告诉我们吧！
排版编辑：肿瘤资讯-Morri
苏公网安备32059002004080号
